Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ABBV-383 Monotherapy vs Standard Available Therapy in Relapsed/Refractory Multiple Myeloma
jRCT2071240020Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of etentamig in multiple myeloma (MM) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Progression Free Survival (PFS) and Rate of Very Good Partial Response or Better (≥ VGPR). Planned start Jun 2024; status: not yet recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2071240020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240020.